Evidence map›Paper›PMID 30500355›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2019

Recent advances in nanoengineering cellulose for cargo delivery.

Amir Sheikhi, Joel Hayashi, James Eichenbaum, Mark Gutin, Nicole Kuntjoro, Danial Khorsandi, Ali Khademhosseini

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amir SheikhiDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Joel HayashiDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
James EichenbaumDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Mark GutinDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Nicole KuntjoroDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Danial KhorsandiDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA.
Ali KhademhosseiniDepartment of Bioengineering, University of California - Los Angeles, 410 Westwood Plaza, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), California NanoSystems Institute (CNSI), University of California - Los Angeles, 570 Westwood Plaza, Los Angeles, CA 90095, USA; Department of Radiological Sciences, David Geffen School of Medicine, University of California - Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA; Department of Chemical and Biomolecular Engineering, University of California - Los Angeles, 5531 Boelter Hall, Los Angeles, CA 90095, USA; Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul 143-701, Republic of Korea. Electronic address: khademh@ucla.edu.

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
Engineering personalized micro-tumor ecosystemsU01CA214411 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, SENGUPTA, SHILADITYA · 2017 to 2021
$3.5M
Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Engineering a naturally derived and highly adhesive surgical sealantR01EB023052 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANNABI, NASIM, KHADEMHOSSEINI, ALI · 2017 to 2022
$2.4M
Targeted chemotherapy delivery and captureR01EB024403 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2017 to 2020
$2.2M
Rapid 3D bioprinting of biomimetic vascularized tissue constructsR01EB021857 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHEN, SHAOCHEN, DOKMECI, MEHMET REMZI · 2016 to 2019
$2.1M
High-Throughput Microenvironment Regulation for ChondrogenesisR01AR066193 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN, KHADEMHOSSEINI, ALI · 2015 to 2020
$2.1M
CIHRNCI NIH HHS U01 CA214411NHLBI NIH HHS R01 HL137193NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR066193NIBIB NIH HHS R01 EB021857NIBIB NIH HHS R01 EB023052NIBIB NIH HHS R01 EB024403
6 · The paper itself

Abstract

The recent decade has witnessed a growing demand to substitute synthetic materials with naturally-derived platforms for minimizing their undesirable footprints in biomedicine, environment, and ecosystems. Among the natural materials, cellulose, the most abundant biopolymer in the world with key properties, such as biocompatibility, biorenewability, and sustainability has drawn significant attention. The hierarchical structure of cellulose fibers, one of the main constituents of plant cell walls, has been nanoengineered and broken down to nanoscale building blocks, providing an infrastructure for nanomedicine. Microorganisms, such as certain types of bacteria, are another source of nanocelluloses known as bacterial nanocellulose (BNC), which benefit from high purity and crystallinity. Chemical and mechanical treatments of cellulose fibrils made up of alternating crystalline and amorphous regions have yielded cellulose nanocrystals (CNC), hairy CNC (HCNC), and cellulose nanofibrils (CNF) with dimensions spanning from a few nanometers up to several microns. Cellulose nanocrystals and nanofibrils may readily bind drugs, proteins, and nanoparticles through physical interactions or be chemically modified to covalently accommodate cargos. Engineering surface properties, such as chemical functionality, charge, area, crystallinity, and hydrophilicity, plays a pivotal role in controlling the cargo loading/releasing capacity and rate, stability, toxicity, immunogenicity, and biodegradation of nanocellulose-based delivery platforms. This review provides insights into the recent advances in nanoengineering cellulose crystals and fibrils to develop vehicles, encompassing colloidal nanoparticles, hydrogels, aerogels, films, coatings, capsules, and membranes, for the delivery of a broad range of bioactive cargos, such as chemotherapeutic drugs, anti-inflammatory agents, antibacterial compounds, and probiotics. SYNOPSIS: Engineering certain types of microorganisms as well as the hierarchical structure of cellulose fibers, one of the main building blocks of plant cell walls, has yielded unique families of cellulose-based nanomaterials, which have leveraged the effective delivery of bioactive molecules.

Indexed as

Drug Delivery SystemsAnimalsCelluloseHumansNanostructuresNanotechnologyCelluloseBacterial celluloseCancer therapyCellulose nanocrystalsCellulose nanofibrilsDrug deliveryHairy nanocelluloseNanocelluloseWound healing

Identifiers

PMID30500355
PMCPMC6385607

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.